慢性乙型肝炎患者miR-625-5p表达水平及其临床意义

摘要/Abstract

摘要： 目的分析慢性乙型肝炎(CHB)患者中miR-625-5p的表达水平,并探讨其在临床诊断和预后中的潜在意义。方法纳入我院2021年2月至2024年2月106例确诊慢性乙型肝炎患者,并选取同期进行体检的93名健康者作为对照组。通过定量实时聚合酶链式反应(qRT-PCR)技术检测所有人员血清中的miR-625-5p表达水平、肝功能及病毒载量。探究miR-625-5p与肝功能、病毒载量的相关性。采用受试者工作特征(ROC)曲线进行miR-625-5p对肝纤维化分期的诊断价值评估。结果对照组miR-625-5p、ALT、AST分别是(1.03±0.15)、(28.26±6.47) U/L、(29.87±5.67) U/L,G0组miR-625-5p、ALT、AST、病毒载量水平为(0.89±0.16)、(83.14±15.46) U/L、(58.36±12.41) U/L、(10.09±3.62) IU/mL,G1~2组为(0.71±0.13)、(99.57±19.82) U/L、(70.13±18.79) U/L、(18.47±5.87) IU/mL,G3~4组为(0.64±0.11)、(118.41±29.59) U/L、(79.68±25.94) U/L、(25.46±8.52) IU/mL。组间比较差异有统计学意义(F=79.216、337.692、130.472、48.862,P<0.05)。miR-625-5p与ALT、AST、病毒载量均呈显著负相关(r=-0.283、-0.212、-0.453,P<0.05)。F0~1组患者miR-625-5p、ALT、AST、病毒载量水平分别为(0.92±0.21)、(75.23±16.48) U/L、(63.17±16.46) U/L、(8.76±4.89) IU/mL,F2~4组患者为(0.68±0.17)、(115.75±27.78) U/L、(74.82±23.67) U/L、(23.79±9.33) IU/mL两组间比较,差异有统计学意义(t=6.204、7.675、2.529、8.600,P<0.05)。ROC曲线分析表明,miR-625-5p在诊断肝纤维化分期方面具有较高的价值,其灵敏度为83.8%,特异度为68.7%,AUC值为0.806,显示出良好的诊断效能。结论 miR-625-5p在CHB患者中的低表达可能与肝脏炎症和肝功能损害有关。miR-625-5p可以作为CHB的潜在生物标志物,用于评估疾病活动度和预后。

关键词: 慢性乙型肝炎, miR-625-5p, 诊断, 预后, 疾病活动度

Abstract: Objective To analyze the serum levels of miR-625-5p in patients with chronic hepatitis B viral (HBV) infection and explore its potential significance in clinical diagnosis and prognosis. Methods The study was conducted from February 2021 to February 2024, including 106 confirmed cases of chronic hepatitis B (CHB), with 93 healthy individuals serving as controls during the same period of time. The serum levels of miR-625-5p, liver function, and HBV viral load were measured using quantitative real-time polymerase chain reaction (qRT-PCR). The relationship between miR-625-5p, liver function, and HBV viral load was investigated. The diagnostic values of miR-625-5p for liver inflammatory grading (G0~G4) and fibrosis staging (F0~F4) were assessed using the receiver operating characteristic (ROC) curve method. Results The values for miR-625-5p, ALT, AST levels in the control group were 1.03±0.15, (28.26±6.47) U/L, and (29.87±5.67) U/L, respectively, The values for miR-625-5p, ALT, AST levels, and HBV viral load were 0.89±0.16, (83.14±15.46) U/L, (58.36±12.41) U/L, and (10.09±3.62) IU/mL in the G0 group; 0.71±0.13, (99.57±19.82) U/L, (70.13±18.79) U/L, and (18.47±5.87) IU/mL in the G1~2 group; and 0.64±0.11, (118.41±29.59) U/L, (79.68±25.94) U/L, and (25.46±8.52) IU/mL in the G3~4 group. The differences of viral load among the groups were statistically significant (F=79.216, 337.692, 130.472, 48.862, P<0.05). There was a significant negative correlation between miR-625-5p, ALT, AST, and HBV viral load (r=-0.283, -0.212, -0.453, P<0.05). The levels of miR-625-5p, ALT, AST, and viral load were (0.92±0.21), (75.23±16.48)U/L, (63.17±16.46)U/L, and (8.76±4.89) IU/mL in patients with F0~1, and 0.68±0.17, (115.75±27.78) U/L, (74.82±23.67) U/L, and (23.79±9.33) IU/mL in patients with F2~4, respectively. The comparisons between these two groups had statistically significant differences (t=6.204, 7.675, 2.529, 8.600, P<0.05). The ROC curve evaluation of miR-625-5p for the diagnosis of liver fibrosis stages showed a sensitivity of 83.8%, a specificity of 68.7%, and an AUC of 0.806, indicating an high diagnostic value. Conclusion Low expression of miR-625-5p in patients with CHB was associated with liver inflammation and liver function impairment. Therefore, miR-625-5p could serve as a potential biomarker for CHB to assess disease’s activity and prognosis.

Key words: Chronic hepatitis B, miR-625-5p, Diagnosis, Prognosis, Disease activity

褚丽, 任传路, 丁俊, 唐敏, 蔡冬平, 周忻. 慢性乙型肝炎患者miR-625-5p表达水平及其临床意义[J]. 肝脏, 2025, 30(12): 1628-1631.

CHU Li, REN Chuan-lu, DING Jun, TANG Min, CAI Dong-ping, ZHOU Xin. The clinical significance of serum miR-625-5p levels in patients with chronic hepatitis B[J]. Chinese Hepatolgy, 2025, 30(12): 1628-1631.

/ 推荐

参考文献

[1] Lim S G, Baumert T F, Boni C, et al. The scientific basis of combination therapy for chronic hepatitis B functional cure[J]. Nat Rev Gastroenterol Hepatol, 2023, 20(4): 238-253.
[2] 邵茉莉,杨敏,张丽,等. 老年乙肝肝硬化合并自发性腹膜炎腹水PCT、HBP、IL-7表达水平对肝功能、肠道屏障功能的影响[J]. 中国老年学杂志,2023,43(22):5455-5457.
[3] Feld J J, Lok A S, Zoulim F. New perspectives on development of curative strategies for chronic hepatitis B[J]. Clin Gastroenterol Hepatol, 2023,21(8):2040-2050.
[4] 秦进,岳宁宁,王双凤,等. 乙肝肝硬化患者肝细胞癌发生风险预测模型的构建[J]. 郑州大学学报(医学版),2023,58(2):217-223.
[5] 陈峰松,蔡瑞,曹小卫,等. 基于识别竞争策略的SERS传感器用于快速和同时检测结直肠癌相关miRNA[J]. 分析测试学报,2025,44(2):265-274.
[6] 李晓荣,高婷,仲佳雯,等. 外泌体miRNA在女性生殖领域研究概况及中医药治疗的研究进展[J]. 辽宁中医杂志,2025,52(2):194-199.
[7] 张汝希,易亚乔,刘涛阳,等. 阿尔茨海默病神经炎症损伤中miRNA介导TLR4信号通路的作用机制及其中西医防治的研究进展[J]. 神经疾病与精神卫生,2025,25(2):144-152.
[8] 丁广智,徐佳,刘畅,等. miR-340-5p及PDCD4在过表达乙肝病毒X蛋白的足细胞中的表达及生物学意义[J]. 病毒学报,2023,39(2):419-426.
[9] Nkongolo S, Mahamed D, Kuipery A, et al. Longitudinal liver sampling in patients with chronic hepatitis B starting antiviral therapy reveals hepatotoxic CD8⁺ T cells[J]. J Clin Invest, 2023, 133(1):e158903.
[10] Ghany M G, Buti M, Lampertico P, et al. Guidance on treatment endpoints and study design for clinical trials aiming to achieve cure in chronic hepatitis B and D: Report from the 2022 AASLD-EASL HBV-HDV Treatment Endpoints Conference[J]. J Hepatol, 2023, 78(5): 1654-1673.
[11] 唐春丽,范淑娟,陶生,等. 血清miR-1298-5p、miR-625-5p、miR-155表达与老年胃癌患者幽门螺杆菌感染程度的相关性[J]. 国际检验医学杂志,2025,46(2):151-156.
[12] 中华医学会肝病学分会,中华医学会感染病学分会.慢性乙型肝炎防治指南(2010年版)[J].中国医学前沿杂志(电子版). 2011,3(1):66-82.
[13] 黄霁,邓秀娟,程显. LINC00839调节miR-625-5p/MSI1轴对子宫内膜癌细胞恶性生物学行为的影响[J]. 中国医科大学学报,2025,54(2):121-126,132.
[14] 连立超,范子玥,张昕,等. 尿KIM-1、NGAL、RBP联合检测在慢性乙肝患者早期肾损伤中的预测价值[J]. 中华临床医师杂志(电子版),2023,17(4):414-418.
[15] 张小红,李江,张然蓉. 慢性乙肝、肝硬化及肝癌患者Treg细胞、IL-10、IL-12表达水平及临床意义[J]. 海南医学,2022,33(15):1921-1924.